iopromide

Trade name: ultravist

Small moleculeapproved

Approved

May 10, 1995

Iopromide is a molecule used as a contrast medium. It is a low osmolar, non-ionic contrast agent for intravascular use. It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT) and CT pulmonary angiograms (CTPAs). It appears to increase the risk of biguanide induced lactic acidosis. Interleukins are associated with an increased prevalence of delayed hypersensitivity reactions after iodinated contrast agent administration. Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision. — NCATS

Clinical trial activity

10 trials · 14 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2005 (NCT00244140)

Timeline

1990s

May 10, 1995
Bayer — Earliest FDA Approval
May 10, 1995
Bayer — NDA Secondary Org
May 10, 1995
Bayer — NDA Organization

2000s

Jan 1, 2005
Bayer — Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Unspecified targetOTHER
Diagnostic agent
contrast mediumRadiopaque
contrast medium radiopaque

Approval history

approvedMay 10, 1995

Chemistry & pharmacology

Loading structure…

SMILES

COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

Mol. weight: 791.1119 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Prescription Only

Oral

Parenteral

Yes

Topical

Black box warning

Sources

Also known as

clarograf
iopromid
iopromide
iopromide
iopromide
iopromide
iopromide
iopromide
iopromide
iopromide
iopromide
iopromide
iopromidum
lopromid
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-n-methylisophthalamide
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-n-methylisophthalamide
n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-n-methylisophthalamide
ultravist
ultravist
ultravist
ultravist
ultravist
ultravist
ultravist 150
ultravist 150
ultravist 240
ultravist 240
ultravist 300
ultravist 300
ultravist 300
ultravist 370
ultravist 370
zk-35760
zk-35760

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03631771	Phase 4	Feb 28, 2019	Bayer, Duke University, General Electric
NCT03292354	N/A	Apr 11, 2017	Maastricht University
NCT03179592	Phase 3	Mar 22, 2017	Bayer, Medical University of South Carolina, University of South Carolina
NCT01580046	Phase 4	Apr 1, 2012	Peking University
NCT01255722	Phase 4	Nov 1, 2010	Guerbet, Kantonsspital Lucerne
NCT00926562	Phase 4	Feb 1, 2009	People's Liberation Army of China
NCT00823628	Phase 4	Feb 1, 2009	Seoul National University
NCT00827788	Phase 4	Dec 1, 2008	Ospedale della Misericordia - Grosseto, University of Milan, University of Siena
NCT00335101	Phase 4	Jun 1, 2006	General Electric
NCT00244140	Phase 3	Oct 1, 2005	Bayer

Showing 10 of 10 trials

Page 1 / 1

Organizations

Research & Development (14)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Bayer	For profit	3	1	2	2005
General Electric	For profit	2	2	1	2006
Duke University	Academic/Hospital	1	0	1	2019
Guerbet	For profit	1	1	1	2010
Kantonsspital Lucerne	Academic/Hospital	1	0	1	2010
Maastricht University	Academic/Hospital	1	1	1	2017
Medical University of South Carolina	Academic/Hospital	1	0	1	2017
Ospedale della Misericordia - Grosseto	Academic/Hospital	1	0	1	2008
Peking University	Academic/Hospital	1	1	1	2012
People's Liberation Army of China	Government	1	1	1	2009
Seoul National University	Academic/Hospital	1	1	1	2009
University of Milan	Academic/Hospital	1	1	1	2008
University of Siena	Academic/Hospital	1	0	1	2008
University of South Carolina	Academic/Hospital	1	1	1	2017

14 organizations

Page 1 / 1

Marketing (2)

Organization	Org type	Relationship	Date
Bayer	For profit	NDA2	May 10, 1995
Bayer	For profit	NDA	May 10, 1995